伊库利珠单抗
非典型溶血尿毒综合征
医学
内科学
队列
人口
危险系数
肾功能
胃肠病学
置信区间
免疫学
补体系统
抗体
环境卫生
作者
Vicky Brocklebank,Patrick R. Walsh,Kate Smith‐Jackson,Thomas M Hallam,Kevin J. Marchbank,Valerie Wilson,Theophile Bigirumurame,Tina Dutt,Emma Montgomery,Michal Malina,Edwin KS Wong,Sally Ann Johnson,Neil Sheerin,David Kavanagh
出处
期刊:Blood
[Elsevier BV]
日期:2023-06-27
卷期号:142 (16): 1371-1386
被引量:88
标识
DOI:10.1182/blood.2022018833
摘要
Historically, the majority of patients with complement-mediated atypical hemolytic uremic syndrome (CaHUS) progress to end-stage kidney disease (ESKD). Single-arm trials of eculizumab with a short follow-up suggested efficacy. We prove, for the first time to our knowledge, in a genotype matched CaHUS cohort that the 5-year cumulative estimate of ESKD-free survival improved from 39.5% in a control cohort to 85.5% in the eculizumab-treated cohort (hazard ratio, 4.95; 95% confidence interval [CI], 2.75-8.90; P = .000; number needed to treat, 2.17 [95% CI, 1.81-2.73]). The outcome of eculizumab treatment is associated with the underlying genotype. Lower serum creatinine, lower platelet count, lower blood pressure, and younger age at presentation as well as shorter time between presentation and the first dose of eculizumab were associated with estimated glomerular filtration rate >60 ml/min at 6 months in multivariate analysis. The rate of meningococcal infection in the treated cohort was 550 times greater than the background rate in the general population. The relapse rate upon eculizumab withdrawal was 1 per 9.5 person years for patients with a pathogenic mutation and 1 per 10.8 person years for those with a variant of uncertain significance. No relapses were recorded in 67.3 person years off eculizumab in those with no rare genetic variants. Eculizumab was restarted in 6 individuals with functioning kidneys in whom it had been stopped, with no individual progressing to ESKD. We demonstrated that biallelic pathogenic mutations in RNA-processing genes, including EXOSC3, encoding an essential part of the RNA exosome, cause eculizumab nonresponsive aHUS. Recessive HSD11B2 mutations causing apparent mineralocorticoid excess may also present with thrombotic microangiopathy.
科研通智能强力驱动
Strongly Powered by AbleSci AI